I mmunoglobulin A nephropathy is the most common glomerulonephritis globally (1) . IgA nephropathy (IgAN) is an autoimmune disease with a known antigen, galactosedeficient IgA 1 , which can elicit an autoantibody response and formation of immune complexes that are deposited in the mesangial area (2) . In histopathology, IgAN is defined by expansion of the mesangial matrix with mesangial cell proliferation and/or mononuclear cell infiltration. Glomeruli contain mainly mesangial deposits of IgA in association with C3 (1-3). Clinically, patients with IgA nephropathy show microscopic and macroscopic hematuria and/or proteinuria. Although the clinical course is generally gradual in patients with IgA nephropathy, progression to renal hypertension, renal anemia, and end-stage kidney disease is not as rare as originally thought. Indeed, in various patient populations, its prognosis can be totally different, ranging from asymptomatic, slow progression to chronic kidney disease and end-stage renal failure in as much as 40% of patients in few months to years. Various risks had been described, which can predict the long-term outcome. Since pathogenesis and radical treatment for IgA nephropathy are still not established, it is necessary to study aggravating factors using various biochemical findings.
Thus, it appears that early screening and subsequent intervention are important for a good prognosis in IgAN patients (2) (3) (4) . Various markers for poor prognosis in IgAN are as follows: (1) heavy proteinuria (2) renal dysfunction at the time of renal biopsy, (3) low serum albumin, (4) male sex, (5) hypertension, (6) age below 30 years. Indeed various studied have addressed the clinical and morphological risk factors related to the risk of IgAN progression. Recently much attention has been directed toward the aggravating effect of hyperuricemia on IgAN (3) (4) (5) . Uric acid is the final oxidation product of purine catabolism and around 70% of uric acid is eliminated by the kidneys (2-6). Many investigation support the hypothesis that elevated uric acid levels might have a harmful effect, leading to dysfunction of endothelial cells, inflammation vasculopathy. Recent studied showed that the serum uric acid level is closely associated with hypertension in hyperuricemic patients and also with the beginning of hypertension (3) (4) (5) (6) . In fact some clinical findings have shown that, lowering uric acid with allopurinol ameliorated endothelial dysfunction in both hyperuricemic subjects and even hypertensive type 2 diabetic patients with normal uric acid levels (3-6). The mechanism by which elevated uric acid causes endothelial dysfunction, is inhibiting nitric oxide synthetase, activating the renin-angiotensin system and causing proinflammation and resultant endothelial dysfunction (6) . Hyperuricemia is also prevalent in patients with chronic kidney disease. In fact, various investigations have shown that hyperuricemia may have a pathogenic role in the development and progression of chronic kidney disease, rather than simply reflecting decreased renal uric acid excretion (1-6). In the study conducted by Sulikowska et hyperuricemic IgAN patients who were randomized to receive allopurinol (100-300 mg/day) or usual therapy for 6 months. They found, hyperuricemia predicts the progression of IgAN independently of baseline estimated glomerular filtration rate and allopurinol may improve the control of blood pressure (11). Thus, it is possible that appropriate treatment by allopurinol be a reasonable modality in these patients (11, 12) . However, to better understand the kidney protective efficacy of allopurinol in IgAN patients, more clinical studies are suggested.
